Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease ; volume:6 ; number:1 ; day:14 ; month:5 ; year:2018 ; pages:1-7 ; date:12.2018
Journal for ImmunoTherapy of Cancer ; 6, Heft 1 (14.5.2018), 1-7, 12.2018
- Urheber
-
Boyiadzis, Michael M.
- Beteiligte Personen und Organisationen
-
Kirkwood, John M.
Marshall, John L.
Pritchard, Colin C.
Azad, Nilofer S.
Gulley, James L.
SpringerLink (Online service)
- DOI
-
10.1186/s40425-018-0342-x
- URN
-
urn:nbn:de:101:1-2018071516144279098663
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:28 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Boyiadzis, Michael M.
- Kirkwood, John M.
- Marshall, John L.
- Pritchard, Colin C.
- Azad, Nilofer S.
- Gulley, James L.
- SpringerLink (Online service)
Ähnliche Objekte (12)
FDA efficiency for approval process of COVID-19 therapeutics
Analysis of FDA's Accelerated Approval Program Performance December 1992–December 2021
The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy
FDA
FDA
FDA
FDA
Pembrolizumab
Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval
FDA approval of lecanemab: the real start of widespread amyloid PET use? — the EANM Neuroimaging Committee perspective
Patient Enrollment per Month (Accrual) in Clinical Trials Leading to the FDA Approval of New Cancer Drugs
FDA efficiency for approval process of COVID-19 therapeutics
Analysis of FDA's Accelerated Approval Program Performance December 1992–December 2021
The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy
FDA
FDA
FDA
FDA
Pembrolizumab
Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval
FDA approval of lecanemab: the real start of widespread amyloid PET use? — the EANM Neuroimaging Committee perspective
Patient Enrollment per Month (Accrual) in Clinical Trials Leading to the FDA Approval of New Cancer Drugs
FDA efficiency for approval process of COVID-19 therapeutics
Analysis of FDA's Accelerated Approval Program Performance December 1992–December 2021
The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy
FDA
FDA
FDA
FDA
Pembrolizumab
Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval
FDA approval of lecanemab: the real start of widespread amyloid PET use? — the EANM Neuroimaging Committee perspective